Zacks Investment Research upgraded shares of Kadmon (NYSE:KDMN) from a hold rating to a buy rating in a report published on Friday. They currently have $4.25 price objective on the stock.
According to Zacks, “Kadmon Holdings, Inc. is a biopharmaceutical company. It engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. The company is developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. Kadmon Holdings, Inc. is headquartered in New York. “
KDMN has been the subject of a number of other reports. HC Wainwright reiterated a buy rating and set a $25.00 target price on shares of Kadmon in a research report on Friday, December 15th. WBB Securities downgraded Kadmon from a hold rating to a sell rating and set a $3.00 target price for the company. in a research report on Monday, October 9th. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of Hold and a consensus price target of $8.65.
Kadmon (NYSE:KDMN) last released its quarterly earnings results on Thursday, November 9th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.38) by ($0.04). The company had revenue of $2.28 million during the quarter, compared to analyst estimates of $5.69 million. Kadmon’s revenue for the quarter was down 60.0% compared to the same quarter last year. During the same period in the previous year, the business earned ($4.24) EPS. sell-side analysts forecast that Kadmon will post -1.61 EPS for the current fiscal year.
Several large investors have recently added to or reduced their stakes in the company. Susquehanna International Group LLP lifted its position in shares of Kadmon by 3,211.2% during the 3rd quarter. Susquehanna International Group LLP now owns 443,135 shares of the company’s stock valued at $1,485,000 after acquiring an additional 429,752 shares during the period. Crestline Management LP acquired a new position in shares of Kadmon during the 3rd quarter worth $2,011,000. Old West Investment Management LLC acquired a new position in shares of Kadmon during the 3rd quarter worth $169,000. Wells Fargo & Company MN raised its holdings in shares of Kadmon by 23.2% during the 3rd quarter. Wells Fargo & Company MN now owns 73,956 shares of the company’s stock worth $247,000 after buying an additional 13,923 shares in the last quarter. Finally, Sphera Funds Management LTD. acquired a new position in shares of Kadmon during the 3rd quarter worth $3,685,000. Hedge funds and other institutional investors own 51.90% of the company’s stock.
WARNING: This piece was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://sportsperspectives.com/2018/01/13/kadmon-kdmn-upgraded-to-buy-by-zacks-investment-research.html.
Kadmon Company Profile
Kadmon Holdings, Inc is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kadmon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon and related companies with MarketBeat.com's FREE daily email newsletter.